Next Investors logo grey

Creso to tap sports and osteoarthritis market with new cannaDOL® range


Published 15-MAR-2018 11:28 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma (ASX:CPH) today revealed it plans to enter into the sports and osteoarthritic market with its innovative CBD-based cannaDOL® product range, comprising both oral nutraceuticals and functional cosmetics.

CPH has joined forces with FRIKE Technologies, the largest independent Swiss manufacturing group, to produce its range of functional cosmetics under the cannaDOL® brand.

The entire cannaDOL® range addresses the need for organic and efficient relief from muscle and joint pain associated with sports injuries and age-related symptoms such as stiffness and arthritis.

The cannaDOL® functional cosmetics products are based on a unique blend of CBD and essential oils that have been clinically studied for supporting the reduction of inflammation and muscle pain.

These will be provided in two different strengths and will be registered as cosmetics in the European Union.

Menthol provides a cooling effect, while the proprietary combination of essential oils heat the targeted area to open up capillaries, penetrating deep into the tissue and stimulating blood circulation in the affected area to accelerate the healing process. The dual modes of action, moreover, provide fast relief for cramped and tense muscles.

CPH’s cannaDOL® oral formulation, on the other hand, is a food supplement in a proprietary delivery technology with high bioavailability and absorption. Its combined CBD, vitamins and minerals formula supports collagen synthesis, reduces fatigue and stimulates the metabolism.

CPH is targeting an expansive market with clearly unmet needs. Oral and topical analgesics make up over 10-20 per cent of the over-the-counter (OTC) market. The European market alone is around €3.5 billion at public price levels. With sports and osteoarthritis customers looking for new organic treatment alternatives, there is scope here for considerable market growth.

However, the size of the market share CPH can secure remains to be seen at this stage, so if considering this stock for your portfolio, do your own research and seek professional financial advice.

CPH marketing and commercial director, Dr. Gian Trepp, said: “Our innovative first in class CBD based oral nutraceuticals and dual action functional cosmetics for muscle and joint pain relief offer additional benefits for sports people and for the ageing population and represent a breaking ground alternative.”

CPH CEO and co-founder, Dr. Miri Halperin Wernli, said: “We are delighted to be partnering with FRIKE Technologies, which has an excellent reputation for manufacturing to the highest quality standards for a range of leading global brands across the pharmaceutical, cosmetic and chemical sectors. Given FRIKE’s significant expertise in proprietary, innovative, Swiss-made formulations, we believe they are the perfect partner.

“People’s perception of cannabis consumption have changed,” Halperin Wernli said. “Cannabis is no longer something just to get ‘high’ on. In the scientific community, CBD advocacy is on the rise, and evidence of its effectiveness in various health issues is growing. As cannabis legalisation begins to spread around the globe, a unique market based on the health appeals of CBD is emerging.

“With our innovative CBD based oral nutraceuticals and functional cosmetics for muscle and joint pain relief in sports and for the aging population, Creso will continue to build our leading position in the global cannabis industry.”

CPH plans to launch the cannaDOL product range with its commercial partners in the first half of 2019.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.